19811-52-0

Basic information

• Product Name: Carbamic acid, [2-oxo-2-[(phenylmethyl)amino]ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 19811-52-0
• Molecular Formula: C14H20N2O3
• Molecular Weight: 264.324
• Mol File: 19811-52-0.mol
• Article Data: 44

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2-oxo-2-[(phenylmethyl)amino]ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-oxo-2-[(phenylmethyl)amino]ethyl]-, 1,1-dimethylethyl ester(19811-52-0)
• EPA Substance Registry System: Carbamic acid, [2-oxo-2-[(phenylmethyl)amino]ethyl]-, 1,1-dimethylethyl ester(19811-52-0)

Safety Data

• Hazardous Substances Data: 19811-52-0(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7461-34-9 N-benzyl-p-chlorobenzamide 
• 54244-69-8 tert-butoxycarbonylamino-acetic acid benzyl ester 
• 100-46-9 benzylamine 
• 4530-20-5 BOC-glycine 
• 3392-07-2 tert-butyl N-{2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethyl}carbamate 
• 622-79-7 benzyl azide 
• 543-27-1 isobutyl chloroformate 
• 537710-06-8 N-Boc-glycine propargyl ester 
• 31954-27-5 N-(tert-butoxycarbonyl)glycine methyl ester 

Downstream Products

• 23583-12-2 N-benzyl-2-(3-benzylureido)acetamide 
• 1448524-05-7 N-(benzylcarbamoylmethyl)-2-(4-fluorophenoxy)acetamide 
• 1448524-04-6 N-(benzylcarbamoylmethyl)-2-(4-bromophenoxy)acetamide 
• 1438895-35-2 C₁₂H₁₄N₂O₂ 
• 1438895-34-1 C₁₂H₁₃ClN₂O 
• 1438895-36-3 C₁₂H₁₄N₂O 
• 1438895-33-0 C₁₉H₂₂N₄O 
• 1438895-32-9 C₂₀H₂₁N₃O 
• 1438895-31-8 C₂₀H₂₁N₃O 
• 1438895-30-7 C₂₃H₂₆N₂O₃ 
• 1438895-29-4 C₂₂H₂₄N₂O₂ 
• 1438895-28-3 C₂₂H₂₄N₂O₂ 
• 1438895-27-2 C₂₂H₂₄N₂O₂ 
• 1229567-38-7 1-benzyl-2,2-dimethyl-5-oxo-2,5-dihydro-1H-imidazole 3-oxide 

Relevant articles and documents

Design, synthesis and in vitro anti-influenza A virus evaluation of novel quinazoline derivatives containing S-acetamide and NH-acetamide moieties at C-4

It is an urgent need to develop more effective anti-influenza agents due to the emergence of highly pathogenic and drug-resistant influenza viruses. Herein, a series of 2,4-disubstituted quinazoline derivatives were designed, synthesized and their antiviral activities against influenza A virus were evaluated. Nine compounds (10a2, 16a, 16e, 16i, 16j, 16n, 16o, 16p and 16r) showed potent activity against influenza A virus (IAV) with IC50 at the low-micromole level (1.29–9.04 μM). Particularly, 16e and 16r possess good anti-IAV activity (IC50: 1.29 μM and 3.43 μM, respectively) and acceptable cytotoxicity, and inhibit the transcription and replication of viral RNA. Together with reasonable PK profiles of 16e, these results suggest their promising potential as candidates for further investigation.

KINASE INHIBITOR

The present invention aims to provide a novel kinase inhibitor and the like, and a therapeutic agent for a disease, a drug discovery screening method and the like utilizing such inhibitor and the like. The compound represented by the following formula (I) and a salt thereof can inhibit plural kinases including LATS (particularly LATS2) which is the major kinase in the Hippo signal transduction pathway. In addition, diseases or tissue damage associated with failure of cellular proliferation can be treated. Therefore, the present invention is beneficial, for example, in the research field of cell functions and diseases, in which the Hippo signal transduction pathway is involved, and the like. Furthermore, it is beneficial in the medical field for the treatment of such diseases and the like. wherein each symbol is as defined in the DESCRIPTION.

Single Electron Transfer-Induced Selective α-Oxygenation of Glycine Derivatives

Modification of amino acids is an important strategy in organic and bioorganic chemistry. In contrast to common side-chain functionalization, backbone modification is much less explored. Especially glycine units seem to be attractive and versatile since a wide range of functionality can be potentially introduced. We report here oxidative modification of glycinates that are stable and enable further functionalization. Selective glycinate enolate oxidation by TEMPO or a FeCp2PF6/TEMPO reagent combination provides stable alkoxyamines in good to excellent yields. The methodology is expanded to glycine-containing dipeptides demonstrating selective oxygenation at the glycine unit. The orthogonal reactivity potential of oxygenated glycines for transformation to other amino acid derivatives is explored.